SCHEMBL2919940

SCHEMBL2919940

COc1nccc2oc(C(=O)N(S)C(=O)Nc3cccc(Oc4ccccc4)c3)cc12

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.44
RAB9A P51151 4/20 0.44
LMNA P02545 2/20 0.44
HPGD P15428 1/20 0.44
KMT2A Q03164 3/20 0.43
RAF1 P04049 1/20 0.41
NPC1 O15118 4/20 0.41
MEN1 O00255 2/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
KDR P35968 2/20 0.40
BRAF P15056 1/20 0.40
NPY5R Q15761 1/20 0.40
F13A1 P00488 1/20 0.39
TGM2 P21980 1/20 0.39
CASP3 P42574 1/20 0.39
SENP8 Q96LD8 1/20 0.39
SENP7 Q9BQF6 1/20 0.39
SENP6 Q9GZR1 1/20 0.39
GRM4 Q14833 1/20 0.39
ALDH1A1 P00352 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2914956 0.88 MAPT (0.43) MAPTRAB9ALMNAHPGDKMT2A
SCHEMBL2919939 0.81 KMT2A (0.48) MAPTRAB9ALMNAHPGDKMT2A
SCHEMBL2941580 0.80 RAB9A (0.44) MAPTRAB9ALMNAHPGDKMT2A
Hydrochloric Acid SCHEMBL2910330 0.79 RAB9A (0.43) MAPTRAB9ALMNAHPGDKMT2A
SCHEMBL4360388 0.79 RAB9A (0.50) MAPTRAB9ALMNAHPGDKMT2A
SCHEMBL2941583 0.77 SPHK1 (0.39) MAPTRAB9ANPC1SMN1; SMN2ALDH1A1
SCHEMBL2914425 0.75 MAOA (0.35) MAPTSMN1; SMN2KDRNPY5RPOLB
SCHEMBL4540505 0.73 LTA4H (0.48) MAPTRAB9AKMT2ANPC1MEN1
SCHEMBL2915045 0.72 KMT2A (0.55) MAPTRAB9ALMNAKMT2ANPC1
SCHEMBL2910244 0.72 NPY5R (0.44) MAPTRAB9ALMNAHPGDKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1709047-B1 AZABENZOFURAN SUBSTITUTED THIOUREAS AS INHIBITORS OF VIRAL REPLICATION ACHILLION PHARMACEUTICALS INC (US) 2010-09-01 EP claimed
US-7439374-B2 Azabenzofuran substituted thioureas; inhibitors of viral replication ACHILLION PHARMACEUTICALS, INC. (US) 2008-10-21 US claimed
JP-2007517887-A 2007-07-05 JP claimed
EP-1709047-A2 AZABENZOFURAN SUBSTITUTED THIOUREAS AS INHIBITORS OF VIRAL REPLICATION Achillion Pharmaceuticals, Inc. (US) 2006-10-11 EP claimed
US-20050228013-A1 Azabenzofuran substituted thioureas; inhibitors of viral replication ACHILLION PHARMACEUTICALS, INC. 2005-10-13 US claimed
WO-2005067900-A2 AZABENZOFURAN SUBSTITUTED THIOUREAS AS INHIBITORS OF VIRAL REPLICATION ACHILLION PHARMACEUTICALS, INC. (US) 2005-07-28 WO claimed
EP-1709047-B1 AZABENZOFURAN SUBSTITUTED THIOUREAS AS INHIBITORS OF VIRAL REPLICATION ACHILLION PHARMACEUTICALS INC (US) 2010-09-01 EP disclosed
US-7439374-B2 Azabenzofuran substituted thioureas; inhibitors of viral replication ACHILLION PHARMACEUTICALS, INC. (US) 2008-10-21 US disclosed
US-20050228013-A1 Azabenzofuran substituted thioureas; inhibitors of viral replication ACHILLION PHARMACEUTICALS, INC. 2005-10-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050228013-A1 Azabenzofuran substituted thioureas; inhibitors of viral replication NAT1, PIGS, ADORA1 MAPT 4359/4885RAB9A 1975/4885LMNA 3932/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.